The aim of the Translational Informatics (Tl) core is to provide the Informatics infrastructure, and to develop, deploy and maintain data systems and applications that optimize the translation of basic scientific discoveries into clinical applications. Tl members are made up of experienced informaticians and clinical research support specialists and analysts with backgrounds in clinical data coordination, biomedical research, molecular biology, computer science, software engineering, and application architecture. The Tl core develops data systems that span a range of users, from individual investigators, to individual programs within the Cancer Center, and to the Cancer Center as a whole. Tl works with researchers, other Cores, and Cancer Center administration to fulfill its goals with the ability to provide customizable informatics solutions for all data needs. Over the next five years, Tl will continue to provide the Cancer Center members with Informatics and computational support for an array of activities, including continued participation in grant applications and expanding efforts as needed to respond to changing needs of funded grants. Tl priorities are to: 1) Access, training, and management of Clinical and Biomedical Software Tools 2) Provide access to Clinical and Biomedical Data for Research 3) Research Data Management Solutions including access to High Performance Compute Cluster and allocated software. Pathway analysis tools (IPA), and design of Data Collection Models 4) Biospecimen Data Management 5) Custom Research Software Development including user interfaces 6) Oversee and provide guidance for Research Data Privacy, Security, and Quality Control 7) Standardize and Harmonize Data Collection Vocabularies and Common Data Elements 8) Maintenance of databases. Patient centric data-warehouse, and associated web sites 9) Custom data services involving specific programming expertise for specialized databases

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-15
Application #
8567914
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
15
Fiscal Year
2013
Total Cost
$497,659
Indirect Cost
$90,775
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications